Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Paper
  • Published:

At last, a weight neutral insulin?

International Journal of Obesity volume 28, pages S41–S46 (2004)Cite this article

Abstract

In the treatment of diabetes, the positive correlation between weight gain and glycaemic control is well known. Inappropriate weight gain has been demonstrated in landmark diabetes studies, with insulin or oral antidiabetic drugs. Weight increase is associated with accelerated deterioration in beta-cell function in type II diabetes, and increases in hypertension and lipid levels in both type I and type II diabetes. Concerns about increasing weight may be a barrier to initiation or to intensification of insulin therapy. Insulin introduction may be delayed in type II diabetes, and patients may under-dose their insulin to avoid gaining weight. Insulin detemir is a new long-acting soluble insulin analogue where protraction is achieved by reversible binding to albumin. As a result, it has consistent absorption and low variability from injection to injection. Studies of insulin detemir in basal-bolus regimens in type I and type II diabetes have shown significantly less weight gain compared with NPH. There is speculation about potential mechanisms for these outcomes and results from ongoing investigations are awaited. The insulin detemir data suggest that weight gain with insulin therapy is not inevitable. The potential therefore exists for improving glycaemic control while maintaining weight stability, resulting in immediate and long-term benefits for patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  1. American Diabetes Association. Tests of glycemia in diabetes. Diabetes Care 2003; 26: S106–S108.

  2. The Diabetes Control and Complications Trial Research Group. Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes 1997; 46: 271–286.

  3. The DCCT Research Group. Weight gain associated with intensive therapy in the diabetes control and complications trial. The DCCT Research Group. Diabetes Care 1988; 11: 567–573.

  4. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type II diabetes (UKPDS 33). Lancet 1998; 352: 837–853.

  5. Purnell JQ, Hokanson JE, Marcovina SM, Steffes MW, Cleary PA, Brunzell JD . Effect of excessive weight gain with intensive therapy of type I diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial. JAMA 1998; 280: 140–146.

    Article  CAS  Google Scholar 

  6. Williams KV, Erbey JR, Becker D, Arslanian S, Orchard TJ . Can clinical factors estimate insulin resistance in type I diabetes? Diabetes 2000; 49: 626–632.

    Article  CAS  Google Scholar 

  7. Yki-Jarvinen H, Ryysy L, Kauppila M, Kujansuu E, Lahti J, Marjanen T, Niskanen L, Rajala S, Salo S, Seppala P, Tulokas T, Viikari J, Taskinen MR . Effect of obesity on the response to insulin therapy in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1997; 82: 4037–4043.

    Article  CAS  Google Scholar 

  8. Tremble JM, Donaldson D . Is continued weight gain inevitable in type II diabetes mellitus? J R Soc Health 1999; 119: 235–239.

    Article  CAS  Google Scholar 

  9. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type II diabetes (UKPDS 34). Lancet 1998; 352: 854–865.

  10. Anderson JW, Kendall CW, Jenkins DJ . Importance of weight management in type II diabetes: review with meta-analysis of clinical studies. J Am Coll Nutr 2003; 22: 331–339.

    Article  Google Scholar 

  11. UK Prospective Diabetes Study Group. UK prospective diabetes study 16 Overview of 6 years' therapy of type II diabetes: a progressive disease (UKPDS 16). Diabetes 1995; 44: 1249–1258.

  12. Jacobs ML, Elte JW, van Ouwerkerk BM, Janssens EN, Schop C, Knoop JA, Hoogma RP, Groenendijk R, Weber RF . Effect of BMI, insulin dose and number of injections on glycaemic control in insulin-using diabetic patients. Studygroup Diabetes Rijnmond (SDR). Neth J Med 1997; 50: 153–159.

    Article  CAS  Google Scholar 

  13. Korytkowski M . When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord 2002; 26 (Suppl 3): S18–S24.

    Article  CAS  Google Scholar 

  14. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, Marks JS . Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003; 289: 76–79.

    Article  Google Scholar 

  15. Gregg EW, Gerzoff RB, Thompson TJ, Williamson DF . Intentional weight loss and death in overweight and obese U.S. adults 35 years of age and older. Ann Intern Med 2003; 138: 383–389.

    Article  Google Scholar 

  16. Myers A, Rosen JC . Obesity stigmatization and coping: relation to mental health symptoms, body image, and self-esteem. Int J Obes Relat Metab Disord 1999; 23: 221–230.

    Article  CAS  Google Scholar 

  17. Musselman DL, Betan E, Larsen H, Phillips LS . Relationship of depression to diabetes types 1 and 2: epidemiology, biology, and treatment. Biol Psychiatry 2003; 54: 317–329.

    Article  Google Scholar 

  18. French SA, Jeffery RW, Murray D . Is dieting good for you? Prevalence, duration and associated weight and behaviour changes for specific weight loss strategies over four years in US adults. Int J Obes Relat Metab Disord 1999; 23: 320–327.

    Article  CAS  Google Scholar 

  19. Snoek FJ . Breaking the barriers to optimal glycaemic control—what physicians need to know from patients' perspectives. Int J Clin Pract Suppl 2002; 129: 80–84.

    Google Scholar 

  20. Peters AL . The clinical implications of insulin resistance. Am J Manag Care 2000; 6 (Suppl): S668–S674 discussion S675–S681.

    CAS  PubMed  Google Scholar 

  21. Zanella MT, Kohlmann Jr O, Ribeiro AB . Treatment of obesity hypertension and diabetes syndrome. Hypertension 2001; 38 (3 Pt 2): 705–708.

    Article  CAS  Google Scholar 

  22. Haffner SM, D'Agostino Jr R, Mykkanen L, Tracy R, Howard B, Rewers M, Selby J, Savage PJ, Saad MF . Insulin sensitivity in subjects with type II diabetes. Relationship to cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study. Diabetes Care 1999; 22: 562–568.

    Article  CAS  Google Scholar 

  23. Wing RR, Klein R, Moss SE . Weight gain associated with improved glycemic control in population-based sample of subjects with type I diabetes. Diabetes Care 1990; 13: 1106–1109.

    Article  CAS  Google Scholar 

  24. Bryden KS, Neil A, Mayou RA, Peveler RC, Fairburn CG, Dunger DB . Eating habits, body weight, and insulin misuse. A longitudinal study of teenagers and young adults with type I diabetes. Diabetes Care 1999; 22: 1956–1960.

    Article  CAS  Google Scholar 

  25. Havelund S, Plum A, Ribel U, Jonassen I, Volund A, Colding-Jorgensen M, Markussen J, Kurtzhals P . The mechanism of protraction of insulin detemir, a long-acting, acylated analogue of human insulin. Pharmaceut Res 2004, in press.

  26. Vague P, Selam JL, Skeie S, De Leeuw I, Elte JW, Haahr H, Kristensen A, Draeger E . Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type I diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care 2003; 26: 590–596.

    Article  CAS  Google Scholar 

  27. De Leeuw I, Vague P, Selam JL, Skeie S, Lang H, Draeger E, Elte JWF . Lower risk of nocturnal hypoglycaemia and favourable weight development in type I diabetic subjects after 12 months treatment with insulin detemir vs NPH insulin. Diab Obes Metab 2004, in press.

  28. Russell-Jones D, Simpson RW, Hylleberg B et al. Effects of once-daily insulin detemir or Neutral Protamine Hagedorn on blood glucose control in patients with type I diabetes using a basal-bolus regimen. Clin Ther 2004; 26: 724–736.

    Article  CAS  Google Scholar 

  29. Pieber T, Grill V, Kristensen A, Draeger W . Treatment with insulin detemir allows flexible timing of administration in subjects with type I diabetes. Diabetes 2003; 52 (Suppl 1): A130.

    Google Scholar 

  30. Standl E, Roberts A, Lang H, Draeger E . Long term efficacy and safety of insulin detemir in subjects with type I diabetes. Favourable weight development and risk reduction of nocturnal hypoglycaemia. Diabetes 2002; 51 (Suppl 2): A115.

    Google Scholar 

  31. Home P, Bartley P, Russell-Jones D . Insulin detemir offers improved glycemic control compared to NPH insulin in people with type I diabetes; a randomized clinical trial. Diabetes Care 2004; 27: 1081–1087.

    Article  CAS  Google Scholar 

  32. Hermansen K, Fontaine P, Kukolja KK . Basal-bolus therapy with insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in patients with type I diabetes. Diabetologia 2004; 47: 622–629.

    Article  CAS  Google Scholar 

  33. Haak T, Tiengo A, Waldhäusl W, Draeger E . Treatment with insulin detemir is associated with predictable fasting blood glucose levels and favorable weight development in subjects with type II diabetes. Diab Obes Metab 2004, in press.

  34. Schwartz MW, Woods SC, Porte Jr D, Seeley RJ, Baskin DG . Central nervous system control of food intake. Nature 2000; 404: 661–671.

    Article  CAS  Google Scholar 

  35. Carlson MG, Campbell PJ . Intensive insulin therapy and weight gain in IDDM. Diabetes 1993; 42 (12): 1700–1707.

    Article  CAS  Google Scholar 

  36. Bagg W, Plank LD, Gamble G, Drury PL, Sharpe N, Braatvedt GD . The effects of intensive glycaemic control on body composition in patients with type II diabetes. Diabetes Obes Metab 2001; 3: 410–416.

    Article  CAS  Google Scholar 

  37. Snoek FJ . Barriers to good glycaemic control: the patient's perspective. Int J Obes Relat Metab Disord 2000; 24 (Suppl 3): S12–20.

    Article  Google Scholar 

  38. Rosskamp RH . Long-acting insulin analogs. Diabetes Care 1999; 22 (Suppl 2): B109–B113.

    PubMed  Google Scholar 

  39. Lindholm A, McEwen J, Riis AP . Improved postprandial glycemic control with insulin aspart A randomized double-blind cross-over trial in type I diabetes. Diabetes Care 1999; 22: 801–805.

    Article  CAS  Google Scholar 

  40. Heller S, Olsen KJ, Draeger E . Lower Risk of Nocturnal Hypoglycemia with Insulin Detemir versus NPH Insulin in People with Diabetes: A Meta-Analysis of Controlled Phase III Trials. Diabetes 2004; 53 (Suppl 2): A487.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Internal Medicine Department IV, Eberhard Karls University Hospital, Tübingen, Germany

    A Fritsche & H Häring

Authors
  1. A Fritsche
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H Häring
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A Fritsche.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fritsche, A., Häring, H. At last, a weight neutral insulin?. Int J Obes 28 (Suppl 2), S41–S46 (2004). https://doi.org/10.1038/sj.ijo.0802749

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijo.0802749

Keywords

This article is cited by

Search

Advanced search

Quick links